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Alzheimer’s disease (AD) and cerebral ischemia (CI) are neuropathologies that are
characterized by aggregates of tau protein, a hallmark of cognitive disorder and
dementia. Protein accumulation can be induced by autophagic failure. Autophagy is
a metabolic pathway involved in the homeostatic recycling of cellular components.
However, the role of autophagy in those tauopathies remains unclear. In this study, we
performed a comparative analysis to identify autophagy related markers in tauopathy
generated by AD and CI during short-term, intermediate, and long-term progression
using the 3xTg-AD mouse model (aged 6,12, and 18 months) and the global CI 2-VO (2-
Vessel Occlusion) rat model (1,15, and 30 days post-ischemia). Our findings confirmed
neuronal loss and hyperphosphorylated tau aggregation in the somatosensory cortex
(SS-Cx) of the 3xTg-AD mice in the late stage (aged 18 months), which was supported
by a failure in autophagy. These results were in contrast to those obtained in the SS-
Cx of the CI rats, in which we detected neuronal loss and tauopathy at 1 and 15
days post-ischemia, and this phenomenon was reversed at 30 days. We proposed that
this phenomenon was associated with autophagy induction in the late stage, since the
data showed a decrease in p-mTOR activity, an association of Beclin-1 and Vps34, a
progressive reduction in PHF-1, an increase in LC3B puncta and autophago-lysosomes
formation were observed. Furthermore, the survival pathways remained unaffected.
Together, our comparative study suggest that autophagy could ameliorates tauopathy
in CI but not in AD, suggesting a differential temporal approach to the induction of
neuroprotection and the prevention of neurodegeneration.
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Introduction
Cerebral ischemia (CI) is considered the third leading cause of death worldwide (Wen et al., 2004;
Zheng et al., 2010), contributing to the development of cognitive decline and dementia, which is
induced by a sedentary lifestyle, unhealthy eating habits, diabetes, and other metabolic diseases
(Boerma, 2011). It is characterized by an occlusion of the cerebral artery, which results in the
deprivation of trophic factors and metabolic substrates, decreased blood ﬂow, and the activation of
cell death pathways (Roberts et al., 2013).
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Excitotoxicity in CI alters the cellular balance (Arundine
and Tymianski, 2004), inducing tau hyperphosphorylation in
early- and intermediate-stage post-ischemia (Wen et al., 2004;
Cespedes-Rubio et al., 2010). This process is associated with a
high incidence of cognitive disorder after stroke (Zheng et al.,
2010; Castro-Alvarez et al., 2011). Our previous studies and
those of others have demonstrated that a reversal of tauopathy
is associated with homeostasis (Kimura et al., 2010; Piedrahita
et al., 2010; Castro-Alvarez et al., 2011) as well as with cognitive
and motor recovery at 30 and 90 days after an ischemic event
(Garrison et al., 2013; Jiang et al., 2013).
Following stroke, three out of four patients develop dementia
(Wen et al., 2004), predominantly Alzheimer’s disease (AD;
Pluta, 2004). Several studies have demonstrated senile plaques
(βA) and amyloid precursor protein (APP) in close proximity
to the ischemic focus (Ikeda et al., 2000; Shi et al., 2000),
suggesting a degree of convergence in the neuropathogenesis
of CI and AD (Jablonski et al., 2011; Song et al., 2013). In
stroke pathophysiology, changes in the phosphorylation pattern
of the tau protein during and after the ischemic event are
observed (Wen et al., 2004). After an infarction, the rapid
dephosphorylation of tau occurs, and after blood reperfusion,
there is evidence of slow but steady hyperphosphorylation, which
causes an accumulation of the tau protein, resulting in long-term
brain damage (Wen et al., 2004).
On the other side, patients with AD suﬀer from a type of
dementia belonging to a family of chronic tauopathies, and AD
is considered the most common form of dementia worldwide
(Schindowski et al., 2006). The intermediate phase of the
progression aﬀects the hippocampus and is associated with a loss
in short-term memory and behavioral disorders (Walker et al.,
2013). The classic hallmarks of AD include amyloid plaques (Aβ)
and neuroﬁbrillary tangles (NFTs), which are closely associated
with a dramatic neuronal loss (Iqbal and Grundke-Iqbal, 2008)
because of the toxic eﬀects generated by cytoplasmic inclusions
(Gong et al., 2005; Iqbal and Grundke-Iqbal, 2008; Martin et al.,
2011).
Tau is a microtubule-associated protein, which is abundant
in axons, promotes polymerization, and modulates the
dynamic stabilization of the actin cytoskeleton (Hashiguchi
and Hashiguchi, 2013). However, it has been shown that the
hyperphosphorilation of tau produces aggregations known
as tauopathies (Spillantini and Goedert, 2013; Kimura et al.,
2014). A common factor in tauopathies is the aberrant
redistribution of tau from the axons to the soma and dendrites
and the accumulation of abnormal ﬁlaments that are highly
phosphorylated and form β-sheets and paired helical ﬁlaments
(PHFs) prior to the formation of NFTs (Spillantini and Goedert,
2013). This process favors loss of neural circuits that support
cognitive dysfunction (Higuchi et al., 2002; Shahani and Brandt,
2002).
Macroautophagy and chaperone-mediated autophagy
(CMA) are induced under conditions of cellular stress,
including starvation and oxidative stress, or under
conditions of altered cellular homeostasis, such as protein
aggregation (Singh and Cuervo, 2011). Autophagy plays
a crucial role in neurodegeneration (Nixon, 2013).
Several studies have shown that autophagy dysfunction
contributes to the pathogenesis of several neurological
diseases, resulting in an abnormal accumulation of
proteins (Murrow and Debnath, 2013), such as in chronic
tauopathies (e.g., AD) and acute tauopathies (e.g., CI;
Nixon and Yang, 2011; Dohi et al., 2012). However, the
mechanisms underlying these pathologies are not clearly
understood.
Therefore, in this study, we performed a comparative analysis
of two types of tauopathies: (a) chronic injury, such as that found
in 3xTg-AD mice model (aged 6, 12, and 18 months) and (b)
acute injury such as that found in CI model in rats (1, 15, and
30 days post-ischemia), to identify the role of autophagy on
tauopathy induced during a short, intermediate and long-term
stages on the progression of both neuropathologies.
Materials and Methods
Animal Procedures
The Wistar rats, NoTg mice [3xTg-AD control containing the
PS1(M146V) transgene], and 3xTg-AD mice [containing the
PS1(M146V), APP(Swe), and tau(P301L) transgenes; Oddo et al.,
2003] were bred in-house in a speciﬁc pathogen-free (SPF) colony
at the vivarium at SIU (Sede de Investigación Universitaria,
University of Antioquia, Medellín, Colombia). The animals were
maintained on a 12-h: 12-h dark:light cycle and received food and
water ad libitum. The animals were handled in accordance with
the Colombian standards (law 84/1989 and resolution 8430/1993)
and NIH guidelines for animal welfare and care (Public Law 99-
158, November 20, 1985, “Animals in Research”). Speciﬁc care
was taken to minimize the animal suﬀering and to reduce the
number of animals used. In total, 60 Wistar rats (aged 3 months,
weighing 250–300 g), 30 NoTg mice, and 30 3xTg-AD mice
(aged 6, 12, and 18 months, weighing 25–30 g) were used. For
the histological and biochemical analyses, ﬁve animals per group
were used (n = 5).
Global Cerebral Ischemia (2VO)
The animals were anesthetized using ketamine (60 mg/kg)
and xylazine (5 mg/kg) and received a 2–4% isoﬂurane and
96% oxygen mixture via an inhalation anesthesia machine.
The body temperature of the animals was monitored using a
rectal thermometer throughout the surgery period, and the body
temperature was maintained at 33 ± 3◦C. A variation of the
global cerebral ischemic model was implemented, involving a 2-
vessel occlusion (2-VO; Marosi et al., 2006) in which the right
common carotid artery (CCA)was permanently occluded and the
left CCA was obstructed for 20 min using a vascular clip. After
the 20 min, the vascular clip was removed to allow reperfusion.
The sham control rats underwent the same procedure without
the CCA occlusion. At 24 h following the completion of the
surgery, a neurological test was performed to evaluate the sensory
and motor abilities of the rats, and a seven-point neurological
score was generated (Yrjanheikki et al., 2005). The animals were
sacriﬁced at 1, 15, and 30 days after ischemia for histological and
biochemical analyses.
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Histology
The anesthetized animals were perfused with saline buﬀer and
4% paraformaldehyde (0.1 M phosphate buﬀer, pH 7.4) using
a Varistaltic Pump Plus (Manostat, Barnaut Company) The
brains were removed, post-ﬁxed in 4% paraformaldehyde at
4◦C for 48 h, and washed with saline buﬀer. The brains were
sectioned into 50-μm slices using a vibrating-blade microtome
(Leica VT1000S; Leica Microsystems), cryopreserved using a
sucrose gradient (7–30%), and stored at −20◦C. The neuronal
population and cell morphology were evaluated using Nissl
staining with toluidine blue (Sigma) of antero-posterior serial
sections for each animal. Brieﬂy, the sections were rinsed in
distilled water and immersed in 1% toluidine blue. The sections
were dehydrated, immersed in xylene, and mounted using
Consultmount R©(Thermo). The tissue was visualized using an
optical microscope (Nikon, Eclipse E200), and the images were
captured using a digital Nikon camera (Sight DS-L1).
Immunohistochemistry
The sections (sham, n = 3; ischemia, n = 5) were treated
with methanol (50% v/v) and hydrogen peroxide (30% v/v) in
0.1 M phosphate-buﬀered saline (PBS; pH 7.4) for 20 min to
inhibit the endogenous peroxidase and were incubated in 0.1 M
phosphate buﬀer and Triton X-100 (0.5%, v/v) for 30 min. The
non-speciﬁc antibody binding sites were subsequently blocked
using BSA (3%) and Triton X-100 (0.3%, v/v) in 0.1 M PBS
for 60 min. The sections were incubated overnight at 4◦C
in anti-PHF-Tau (AT-8, monoclonal mouse, 1:500; Pierce),
which recognizes pSer202/Thr205; PHF-1 monoclonal antibody
(a kind gift from P. Davies, Feinstein Institute for Medical
Research, Manhasset, NY, USA), which recognizes pSer396/404
in the tau protein; LC3-II polyclonal rabbit antibody (1:250;
Cell Signaling Technology); and NeuN monoclonal antibody
(1:1,000, Chemicon R©). Next, the cells were washed several
times in PBS. The sections were incubated with biotinylated
mouse and rabbit secondary antibodies (1:250; Pierce) for
90 min at room temperature (RT). The sections were washed
four times in PBS, incubated with avidin/biotin peroxidase
(1:250; Pierce,) for 1 h, and visualized using diaminobenzidine
(DAB; Sigma-Aldrich). The sections incubated in the absence
of primary antibodies were used as the negative controls. The
slides were dehydrated, washed with PBS, and mounted onto
coverslips using Consultmount R© (Thermo). The tissue sections
were visualized using an optical microscope (Nikon, Eclipse
E200), and the images were captured using a digital Nikon
camera (Sight DS-L1). Intensity of immunoreactivities was
determinated by binary system detected by Image J software from
NIH.
Electron Microscopy
Fifty-μm slices from three sham and three ischemic rats perfused
with saline buﬀer and 4% paraformaldehyde (0.1 M phosphate
buﬀer, pH 7.4) were incubated with 0.5% glutaraldehyde in TBS
(150 mM NaCl, 30 mM Tris, pH 8.2) for 2 min. Grids were
negatively stained for 40 s in uranyl acetate (2%). Samples were
examined in a JEM-1010 Transmission Electron Microscope
(Jeol, Tokyo, Japan) in the Electron Microscopy Service at the
Centro de Biología Molecular Severo Ochoa, Madrid.
Western Blotting Analyses
The animals were sacriﬁced, and the cerebral cortices were
dissected, immediately frozen in liquid nitrogen, and stored at
−80◦C prior to use. The samples were lysed in 10 mM Tris
(pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10%
glycerol, 1% NP40, 1 nM orthovanadate, 5 mM NaF, 1 mM
phenylmethylsulfonyl ﬂuoride, and a protease inhibitor cocktail
(Sigma-Aldrich; Cardona-Gomez et al., 2004). The lysates
(containing ∼30 μg of proteins, quantiﬁed using the Bradford
method) were loaded onto 8 and 15% electrophoresis gels
and transferred onto nitrocellulose membranes (GE Healthcare)
at 250 mA for 2 h using an electrophoretic transfer system.
The membranes were incubated overnight at 4◦C in AT-
8 anti-PHF-Tau (rat monoclonal antibody) (1:500; Pierce),
rabbit anti-Beclin-1 (1:500; Cell Signaling Technology), rabbit
anti-LC3B (1:500; Cell Signaling Technology), rabbit anti-
LAMP2-A (1:1,000; Sigma-Aldrich), rabbit anti-mTOR (1:500;
Cell Signaling Technology), anti-Vps34 (1:500; Cell Signaling
Technology), anti-Hsc70 (1:1,000; Abcam ab137806), anti-HSP90
(1:1000; Santa Cruz Biotechnology Inc.), anti-CHIP (1:1,000;
Sigma-Aldrich), PHF-1 monoclonal antibody (Donated by P.
Davies, Feinstein Institute for Medical Research, Manhasset,
NY, USA), and mouse anti-β actin and anti-tubulin (1:4,000;
Promega). IRDye 800CW goat anti-mouse or anti-rabbit (LI-
COR; 1:5,000) and anti-mouse IgG or anti-rabbit IgG peroxidase-
conjugated antibodies (Pierce Biotechnology; diluted 1:10,000)
were used as the secondary probes. The blots were developed
using the Odyssey Infrared Imaging System. To minimize
interassay variation, samples from all of the experimental groups
were processed in parallel.
Immunoprecipitation
The animals (n = 5 for each experimental group) were sacriﬁced
by decapitation, and the brains were quickly removed. The
cerebral cortices obtained from the 3xTg-AD mice and sham-
and post-ischemic rats were dissected and frozen at −80◦C
until further analysis. The samples were homogenized in lysis
buﬀer containing 150 mM NaCl, 20 mM Tris (pH 7.4), 10%
glycerol, 1 mM EDTA, 1% NP40, 100 μM phenylmethylsulfonyl
ﬂuoride, 1 μg/ml aprotinin and leupeptin (Sigma), and 100 μM
orthovanadate. The lysates were clariﬁed by centrifugation
at 14,000 rpm for 5 min. A protein assay was performed,
and 250 μg of protein was incubated overnight at 4◦C in
the presence of Beclin-1 or Vps34 antibodies (1:250, Cell
Signaling Technology). Protein G-sepharose beads were added,
and the samples were incubated for an additional 2 h at RT.
The immune complexes were washed three times using an
immunoprecipitation lysis buﬀer prior to the SDS-PAGE and
immunoblotting. The proteins were separated using 10% SDS-
PAGE, transferred onto nitrocellulose membranes (Amersham),
and probed with Beclin-1 (1:1,000; Cell Signaling) or Vps34
antibodies (1:500; Calbiochem). The lysates were used as the
positive controls, and incubation with IgG peptide was used as
the negative immunoprecipitation control.
Frontiers in Aging Neuroscience | www.frontiersin.org 3 May 2015 | Volume 7 | Article 84
Villamil-Ortiz and Cardona-Gomez Autophagy and tauopathy markers comparison
mTOR Kinase Activity
The K-LISA mTOR Activity Kit (Merck/Millipore) was used to
measure the mTOR kinase activity. The cerebral cortical lysates
obtained from the 3xTg-AD mice and ischemic rats and their
respective controls (NoTg mice and sham rats, respectively) were
homogenized in 50 mM Tris-HCl (pH 7.4), 100 mM NaCl,
50 mM β-glycerophosphate, 10% glycerol, Tween 20, 1 mM
EDTA, microcistin LR, 20 mM NaF, and 25 mM protease
inhibitor cocktail. The samples were clariﬁed of insoluble
material by centrifugation at 20,000 rpm for 10 min at 4◦C. The
mTOR primary antibody (6 μg) was added to the supernatants
and incubated for 1 h at 4◦C. Next, G Sepharose beads were
added, and the samples were incubated with stirring for 60 min at
4◦C and centrifuged at 4,000 rpm for 5 min at 4◦C. The pellet was
washed using 1X kinase assay buﬀer and incubated in 2X assay
buﬀer and the mTOR kinase substrate WS (working solution)
for 30 min at 30◦C. The enzymatic reaction was terminated
using the kinase stop solution, and the supernatant was added
to the glutathione-coated wells and incubated for 60 min at 30◦C,
followed by two washes and incubation for 1 h at RT with 100 μl
anti-WS p70S6K-T389. Next, the samples were washed three
times using 100-μl HRP secondary antibody for 1 h. Finally,
the colorimetric reaction was stopped using ELISA stop solution,
and the absorbance was read at 450 nm. The colorimetric values
reﬂected the amount of mTOR kinase activity.
Immunofluorescence
The mouse and rat brains were ﬁxed in 4% paraformaldehyde
in PBS, cryopreserved with 30% sucrose, and stored at 20◦C.
The brains were cut into 50-μm coronal sections using a
vibratome (Leica 1000) and treated with 50 mM NH4Cl for
10 min at RT. The tissue sections were preincubated for 1 h
in 1% BSA containing 0.3% Triton X-100 in 0.1 M P and
incubated with primary antibodies, polyclonal anti-LC3B (1:200,
Cell Signaling Technology) and monoclonal PHF-1 overnight at
4◦C. The secondary antibodies were conjugated to Alexa 594
and 488 ﬂuorophores (Molecular Probes). The sections were
visualized using a Confocal-DSU Olympus IX-81 microscope
and analyzed as individual images for LC3, Hoechst, and PHF-
1 immunoﬂuorescence. The deconvolution, maximal projection,
and ﬂuorescence intensity were determined using the Image
Scope-Pro software (Media Cybernetics) and Cell software
(Olympus).
Statistics Analysis
In each experimental group, ﬁve animals were histologically and
biochemically analyzed (n = 5, represents the number of animals
used for the statistical analyses). The homogeneity of the variance
test was applied prior to the statistical analysis. Parametric data
were compared using one-way analysis of variance (ANOVA)
with Tukey’s post hoc test to compare several independent groups.
The Fisher Z-test was used to normalize the values, and the
data were analyzed using ANOVA with Tukey’s post hoc tests.
The analyses were performed using SPSS 18.0 and GraphPad
Prism version 5.00 software (University of Antioquia license).
The data were expressed as the mean ± the SEM with p < 0.05∗
and p < 0.01∗∗. To diminish interassay variation, all of the
sample groups were processed in parallel. In addition, the data
obtained for the 3xTG-AD mice were analyzed and compared
with the average value of the internal control for the NoTg mice
for each age group (6, 12, and 18 months). The ischemic rats
were compared to the sham rats for each assay and at each
post-ischemia time point (1, 15, and 30 days).
Results
Comparative Analysis of Neuronal Loss in
the Primary Somatosensory Cortex of
3xTg-AD Mice and Global Cerebral Ischemic
Rats
Neuronal loss is a major neuropathological indicator used to
measure the degree of alteration in nervous tissue (Buchman
et al., 2013) and has been previously demonstrated in both
AD and CI (Cespedes-Rubio et al., 2010; Abuhassan et al.,
2011). We analyzed the temporal course of neuronal nuclei
immunoreactivity (NeuN; Mullen et al., 1992; Wolf et al.,
1996) in the somatosensory cortex, as common aﬀected area
during acute and chronic injury, during the short-term,
intermediate, and long-term stages of disease in the 3xTg-
AD and global CI (2-VO) models. We observed changes
in NeuN immunoreactivity levels in the 3xTG-AD mice at
6 months of age (4,488 ± 177 nuclei) compared with the
NoTg mice (4,886 ± 460 nuclei). However, a signiﬁcant
decrease in the NeuN immunoreactivity levels was observed at
12 months (3,787 ± 43 nuclei) and 18 months (3,319 ± 222)
compared with the control group at these ages (4,662 ± 294
and 4,701 ± 562 cores, respectively; Figure 1A). These data
conﬁrmed a progressive neuronal loss in AD, mainly during
the late stages of the disease (Hubbard and Anderson, 1985;
Scheﬀ and Price, 2006; Padurariu et al., 2012; Reijmer et al.,
2013).
In the global CI rat model, the penumbral area in the
somatosensory cortex, which is closest to the focus in
the region of the middle cerebral artery, demonstrated a
signiﬁcant reduction in the NeuN immunoreactivity (Figure 1B)
at day 1 (2,322 ± 109 nuclei) and day 15 (2,531 ± 185
nuclei) post-ischemia compared with the control rats
(2,780 ± 158 and 3,395 ± 206, respectively). Interestingly,
the NeuN immunoreactivity recovered at 30 days post-
ischemia (2,990 ± 179 nuclei) compared to the internal
control group (2,858 ± 61 nuclei; Figure 1B). These results
conﬁrmed previous ﬁndings demonstrating a neuronal loss
in the somatosensory cortex during the acute phase post-
ischemia (Guadagno et al., 2008; Kiran, 2012; Carrera et al.,
2013).
Hyperphosphorylated tau Progressively
Increases in the Somatosensory Cortex of
3xTg-AD Mice but is Reversed in the Late
Stage in Ischemic Rats
The aggregation of hyperphosphorylated tau protein has been
described as one of the main histopathological hallmarks that
lead to neuronal cell death and promote neurodegenerative
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FIGURE 1 | Temporal course of the neuronal population and
hyperphosphorylated tau in 3xTg-AD mice and 2VO cerebral ischemia in
rats. (A) NeuN immunoreactivity (IR) decreased at 6 (p ≤ 0.0212), 12
(p ≤ 0.0213), and 18 months (p ≤ 0.0422) in the SS-Cx of the 3xTgAD mouse
model. (B) NeuN IR decreased at 1 (p ≤ 0.0403) and 15 days (p ≤ 0.0417)
post-ischemia, while increased at 30 days post-ischemia (p ≤ 0.2616). Both
models were compared with the internal control groups, NoTg and sham
animals respectively n = 3 animals/group. Scale bar, 150 μm; magnification 10X
(insert 100X). (C) AT-8 IR increased at 12 months (p ≤ 0.0001) and 18 months
(p ≤ 0.0001) in the SS-Cx of the 3xTgAD mice compared with the 3xTg-AD
mice at 6 months (p ≤ 0.001) and NoTg mice. (D) AT-8 IR increased at 1
(p ≤ 0.0001) and 15 days (p ≤ 0.0001) post-ischemia in rats, while it was
decreased at 30 days post-ischemia (p ≤ 0.1388), compared with the sham
rats. Magnification, 40X (insert 100X); n = 4–5. (E) Western blots showing
representative bands of AT-8 and PHF-1 increased at 12 (p ≤ 0.001) and 18
(p ≤ 0.02) months in SS-Cx total lysates from 3xTg AD. (F) AT-8- (p ≤ 0.011)
and PHF-1 (p ≤ 0.020) protein levels increased at 15 days post-ischemia
compared with the internal controls. β-actin was used as the loading control.
The data are expressed as the mean ± SEM; n = 4–5; ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.0001.
diseases and dementia (Kosik and Shimura, 2005). We evaluated
the temporal course of phosphorylated tau using AT-8 and
PHF-1 antibodies in short-term, intermediate, and long-term
disease progression in the somatosensory cortex of chronic
injuries, such as in AD (at 6, 12, and 18 months) and in
acute injury, such as CI (2VO at 1, 15, and 30 days post-
ischemia). Our data show increased AT-8 immunoreactivity
in the 3xTg-AD mice at 12 and 18 months compared with
the 3xTg-AD mice at 6 months and the respective controls
(NoTg; Figure 1C). These observations were supported by the
increased AT-8 protein levels at 12 months and PHF-1- protein
levels at 18 months in the 3xTgAD mice compared with the
internal controls for each age group (Figure 1D), conﬁrming
the direct relationship between tauopathy and disease progress,
as previously described (Oddo et al., 2003). In addition, these
ﬁndings conﬁrmed the inverse relationship of tauopathy with
neuronal loss in an advanced stage of the neuropathology (aged
12 and 18 months).
Compared with the ischemic rats, the levels of AT-8
immunoreactivity were increased at 1 and 15 days post-ischemia.
However, these levels were signiﬁcantly decreased at 30 days
after stroke compared with the internal control (Figure 1E).
These observations were supported by the statistically signiﬁcant
increase in the AT-8- and PHF-1 protein levels at 15 days post-
ischemia compared with the internal control (Figure 1F). These
ﬁndings demonstrated early tauopathy induced by acute injury
(1 and 15 days) via global CI (2VO), which was reversed at
30 days.
mTOR Kinase Activity is Upregulated in the
Late Stage Progression in 3xTgAD Mice and
Downregulated in the Late Stage
Progression in Cerebral Ischemic Rats
The pAkt/mTOR pathway is involved in the control of autophagy
(Spilman et al., 2010; Chong et al., 2012). In this study, we
evaluated the relationship between the activation of the mTOR
pathway and tau hyperphosphorylation. We determined that
the p-Ser473 Akt protein levels but not the p-Ser2448 mTOR
protein levels were signiﬁcantly increased in the NoTg animals at
18 months compared with the NoTg mice at 6 and 12 months.
However, there was a signiﬁcant increase in p-Ser473 Akt
(Figure 2A) and p-Ser2448 mTOR at 6 months (Figure 2B)
as well as an increase at 18 months in the 3xTg-AD mice
(Figure 2B). These ﬁndings were clearly supported by the
increase in mTOR activity at 6 and 18 months without any
signiﬁcant changes at 12 months in the 3xTg-ADmice compared
with the age-matched NoTg control mice (Figure 2C). Increased
levels of Bcl-2, which acts downstream of the Akt/mTOR
pathway, were observed in the NoTg mice at 18 months,
even in the absence of changes in the level and activity
of p-Ser2448 mTOR (Figure 2D). Nevertheless, there was a
signiﬁcant reduction in the levels of Bcl-2 in the 3xTg-AD mice
at 18 months (Figure 2D), and no changes were observed at
the other time points compared with the control groups. These
ﬁndings indicated that the NoTg mice demonstrated an increase
in the level of Akt/Bcl-2 proteins associated with age. However,
the 3xTgADmice demonstrated a defective pathway, as indicated
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FIGURE 2 | Altered p-AKT/p-mTOR activation in the cerebral cortex of
3xTgAD mice compared with cerebral ischemia in rats. Representative
bands from SS-Cx lysates of 3xTgAD and ischemic rats were evaluated by
Western blotting. (A) p-Ser473 Akt protein levels increased in NoTg mice at
18 months (p ≤ 0.005) compared with t NoTg mice at 6 and 12 months. Also,
p-Ser473 Akt protein levels increased at 6 months in 3xTg-AD (p ≤ 0.0045).
(B) p-Ser2448 mTOR protein levels increased at 6 (p ≤ 0.0150) and 18
(p ≤ 0.0339) months in 3xTgAD mice, (C) mTOR activity increased at
18 months (p ≤ 0.017), (D) Bcl-2 protein levels Increased in NoTg mice at
18 months (p ≤ 0.045), and there was a reduction in the levels of Bcl-2 in the
3xTg-AD mice at 18 months (p ≤ 0.038). (E) p-Ser473 Akt decreased at
15 days (p ≤ 0.0258) and 30 days (p ≤ 0.0147) post-ischemia, (F) similarly
p-Ser2448 mTOR decreased at 15 days (p ≤ 0.0056) and 30 days (p ≤ 0.0183)
after cerebral ischemia. (G) mTOR kinase activity decreased at day 30
post-ischemia (p ≤ 0.0330). (H) No significant changes were detected in the
Bcl-2 protein levels in any post-ischemia time point. The data were normalized
against the internal control for each time point for the NoTg mice (A–D) and
sham rats (E–H). β-actin and β-III tubulin were used as the loading controls. The
data are shown in the bar graph as arbitrary units (AUs). The data are presented
as the mean ± SEM; n = 3–5; ∗p < 0.05; ∗∗p < 0.001.
by the increase in mTOR kinase activity and the signiﬁcant
reduction in Bcl-2 levels at the late stage of the disease.
In contrast, the ischemic rats demonstrated a signiﬁcant
decrease in p-Ser473 Akt and p-Ser2448 mTOR protein levels
at 15 and 30 days after CI, respectively (Figures 2E,F), which
was supported by the signiﬁcant downregulation inmTOR kinase
activity at day 30 in the ischemic group compared with the
sham rats (Figure 2G). Finally, no signiﬁcant changes were
detected in the Bcl-2 protein levels in any of the post-cerebral
ischemic time points compared with the controls (Figure 2H).
These ﬁndings suggested that the low levels of p-Akt and
mTOR kinase activity and the maintenance of basal levels of
Bcl-2 promoted cellular homeostasis at 30 days post-ischemia,
which was consistent with the neuronal population recovery and
decrease in hyperphosphorylated tau.
Macroautophagy-Associated Proteins
Decreased in the Late Stage of 3xTg-AD, but
were Induced in Late Stage of Cerebral
Ischemia
The Beclin-1 and Vps34 proteins are crucial for the assembly
of the phagophore assembly site (PAS; Funderburk et al., 2010),
and LC3B is an autophagosomal marker (Kang et al., 2011)
that is associated with autophagic ﬂux (Rubinsztein, 2012).
To determine the role of macroautophagy in the tauopathy
generated after acute (CI) and chronic (3xTg-AD) injury, we
performed a comparative analysis of these proteins in both
models. We found that Beclin-1 and Vps34 increased at
the early stage of progression (6 months) in the 3xTg-AD
mice (Figures 3A,B) compared with the controls. Although
a Vps34/Beclin-1 association was observed at 6 months, this
association was not reciprocally conﬁrmed in the detection of the
inverse Beclin-1/Vps34 complex (Figure 3C). The Vps34/Beclin-
1 association was progressively lost at 12 and 18 months
and was signiﬁcantly reduced in the late stage progression
(18 months) in the 3xTg AD mice (Figure 3C). In addition,
these data were supported by the increase in the LC3B-
II/LC3B-I ratio (Figure 4A) and LC3B puncta formation at
6 months (Figure 4B). However, a progressive decrease in
the LC3B-II/LC3B-I ratio was observed at 18 months without
any changes in the LC3B puncta compared with the controls
(Figure 4B) in the somatosensory cortex of the 3xTg-AD
mice.
Nevertheless, there was a signiﬁcant increase in Beclin-1
at 15 days in the somatosensory cortex of the ischemic rats
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FIGURE 3 | Macroautophagy effects on the cerebral cortex of
3xTgAD mice compared with cerebral ischemia in rats.
Representative bands from SS-Cx lysates of 3xTgAD and ischemic rats
were evaluated by Western blotting and immunoprecipitation. (A) Beclin-1
(p ≤ 0.043) and (B) Vps34 (p ≤ 0.029) increased in 3xTg-AD at
6 months. (C) The Vps34/Beclin-1 association was lost at 12 and
18 months. (D,E) Beclin-1 increased at 15 days in Ischemic rats
(p ≤ 0.029) and Vps34 was reduced at 1 day (p ≤ 0.021) and 30 days
(p ≤ 0.007). (F) Association between Beclin-1 and Vps34 was detected
at 30 days and Vps34/Beclin-1 complex formation at 15 and 30 days
post-ischemia. The data from the 3xTgAD mice and ischemic rats were
normalized against the internal control for each time point in the NoTg
mice and sham rats, respectively. β-actin was used as the loading
control. The data are shown in the bar graph as AUs. IgG was used as
the loading control in the immunoprecipitation assay. The data are
presented as the mean ± SEM; n = 3–5; ∗p < 0.05; ∗∗p < 0.001.
(Figure 3D), although Vps34 was signiﬁcantly reduced at 1
and 30 days and did not change at 15 days after ischemia
(Figure 3E). However, a signiﬁcant association between Beclin-
1 and Vps34 was detected at 30 days, which was supported
by the Vps34/Beclin-1 complex formation at 15 and 30 days
post-ischemia (Figure 3F). The LC3B-II/LC3B-I ratio was
increased on day 1 and at 30 days post-ischemia (Figure 4C),
which support the LC3B immunoreactivity puncta distribution
was signiﬁcantly increased at 1 and 30 days post-ischemia
(Figure 4D) compared with the internal controls. These data
demonstrated a major variation at 1 day post-ischemia with
an apparent lack of PAS formation (Beclin-1/Vps34), but an
increase in LC3B-positive autophagosomes. Although PAS and
LC3B puncta were detected at 30 days after stroke, there
was a concomitant reduction in hyperphosphorylated tau at
this late stage post-ischemia (Figure 1E). Which could be
supported by detection of bigger autophago-lysosome (ALs;
36/106 total ALs, 35%) and bubble-like (BL; 64/129 total
ALs, 49%) on cerebral cortex of ischemic rats at 30 days,
compared respect to the detection of AL (20/115 total ALs,
17%) and BL (21/101 total Als, 20 %) on cerebral cortex
from sham rats analyzed by transmission electron microscopy
(Figure 5).
LC3B Immunofluorescence is Increased
When Hyperphosphorylated tau is Reduced
in Late-Stage Cerebral Ischemia in Rats
but is Decreased in the Tauopathy in
3xTg-AD Mice
To conﬁrm the interdependency between the levels of
hyperphosphorylated tau and macroautophagy, we evaluated
the immunoﬂuorescence intensity of PHF-1 and LC3B in
the primary somatosensory cortex in the short, intermediate,
and long-term progression of chronic injury (3xTg-AD at
6, 12, and 18 months, respectively) and acute injury (CI –
2VO at 1, 15, and 30 days post-ischemia). We observed a
signiﬁcant increase in the ﬂuorescence intensity of PHF-1
immunoreactivity in the 3xTg-AD mice at 12 and 18 months
compared with the internal controls at each time point.
Interestingly, we observed a signiﬁcant reduction in the
ﬂuorescence intensity of LC3B in the 3xTg-AD mice at
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FIGURE 4 | LC3B immunoreactivity in the cerebral cortex of 3xTgAD
mice and in cerebral ischemic rats. (A) Increase in the LC3B-II/LC3B-I ratio
(p ≤ 0.010) and (B) LC3B puncta formation at 6 months (p ≤ 0.0013) in
3xTg-AD. (C) The LC3B-II/LC3B-I ratio was increased on day 1 (p ≤ 0.0239)
and at 30 days post-ischemia (p ≤ 0.0032). (D) LC3B immunoreactivity puncta
formation was increased at 1 (p ≤ 0.0125) and 30 days (p ≤ 0.0058)
post-ischemia. The bands are representative of LC3B-I and LC3B-II in AD and
CI, respectively. LC3B-I and LC3B-II protein levels and ratios were evaluated
using Western blots. β-actin was used as the loading control n = 5–6. The data
are shown as AUs. LC3B immunoreactivity was converted into a binary system
for densitometric analyses. An LC3B puncta pattern was observed.
Magnification, 100X; scale bars, 5 μm; n = 3. The data were compared to the
internal control values for each time point in the disease progression. The data
are expressed as the mean ± SEM; ∗p < 0.05; ∗∗p < 0.001.
18 months (Figure 6A). Taken together, these ﬁndings suggested
that formation of autophagosomes is altered, since LC3B is
decreased, which could favor the Tau aggregation in advanced
stages of chronic injury, such as in the 3xTg-AD model
mice.
However, when we assessed the somatosensory cortex of the
ischemic rats, we found a signiﬁcant increase in the PHF-1
ﬂuorescence intensity at 1 and 15 days post-ischemia, which was
reversed on day 30 post-ischemia, compared with the controls
for each time point. Interestingly, we observed an up-regulation
in the ﬂuorescence intensity of LC3B at 1 and 30 days post-
ischemia (Figure 6B) compared with the temporal course of the
sham animals. These results were consistent with our previous
data, suggesting that autophagosomes formation were increased
at late stage post-ischemia, which could be associated with
decline of the hyperphosphorylated tau aggregates in the same
stage.
Hsc70 and LAMP2 are Differentially Affected
in Chronic and Acute Tauopathies
Chaperone-mediated autophagy demonstrates an
interdependency with macroautophagy (Kaushik et al., 2008)
in the promotion of homeostasis (Kon and Cuervo, 2010).
Therefore, we analyzed several CMA-related proteins in the
context of tauopathy progression. Our data showed that the
chaperone-assisted ubiquitin ligase (CHIP) was not modiﬁed
(Figure 7A), Hsc70 was down-regulated at 12 and 18 months in
the 3xTg-AD mice (Figure 7B) and that Hsp90 was increased
at 6 months, but there were not changes in these protein
levels at 12 and 18 months (Figure 7C). LAMP2 (lysosome
membrane marker) protein levels were unaltered compared to
the controls (Figure 7D). These results suggested a negative
eﬀect on the CMA pathway, where low Hsc70 levels were
used as an indicator of an alteration at late-stage AD in the
3xTg-AD mice.
Frontiers in Aging Neuroscience | www.frontiersin.org 8 May 2015 | Volume 7 | Article 84
Villamil-Ortiz and Cardona-Gomez Autophagy and tauopathy markers comparison
FIGURE 5 | Autophago-lysosomes at 30 days post-ischemia. Detection
of Autophago-lysosomes (ALs) and bubble-like (BL). Representative images
obtained from SS-Cx cortex of sham and ischemic rats at 30 days
post-stroke by TEM.
In the somatosensory cortex of the ischemic rats, we
demonstrated that CHIP was unaltered at the diﬀerent stages of
the disease (Figure 7E).Moreover, the Hsc70 and LAMP2 protein
levels demonstrated an up-regulation at the intermediate stage
(15 days) post-stroke, although these levels remained unchanged
at 30 days (Figures 7F,H). And the Hsp90 levels were increased at
1 and 15 days and signiﬁcantly reduced at 30 days after ischemia
(Figure 7G). These ﬁndings suggested that in an intermediate
time point post-ischemia the CMA pathway could be induced,
favoring the degradation of tau hyperphosphorylated, which was
consistent with higher levels of Hsp90, Hsc70, and LAMP2.
Moreover, hyperphosphorylated tau was reversed at 30 days after
stroke when the macroautophagy markers were increased.
Discussion
Our study present by ﬁrst time a comparative analysis of
chronic and acute tauopathies in animal models. Our results
suggested that there was an increase of autophagy-related
markers, coincident with the inhibition of the Akt/mTOR
pathway at late-stage (30 days) post-ischemia, when reduced the
tauopathy and decreased neuronal loss in the CImodel. However,
these changes were not observed at the late-stage (18 months)
of 3xTg-AD progression, favoring the formation of NFTs and
cerebral impairment. These ﬁndings suggest a time window for
neuroprotective therapy for the induction of autophagy.
FIGURE 6 | LC3B and PHF-1 immunofluorescence in the cerebral
cortex of 3xTgAD mice and in cerebral ischemic rats. LC3B and
PHF-1 immunofluorescence was detected in the SS-Cx of 3xTgAD mice
and cerebral ischemic rats. (A) PHF-1 fluorescence intensity increased in
3xTg-AD mice at 12 (p ≤ 0.0003) and 18 months (p ≤ 0.0233), and
LC3B fluorescence intensity decreased in 3xTg-AD mice at 18 months
(p ≤ 0.0499). (B) PHF-1 fluorescence intensity increased at 1
(p ≤ 0.0001) and 15 days post-ischemia (p ≤ 0.0079), and a reduction
at 30 days (p ≤ 0.1191) post-ischemia, and LC3B fluorescence intensity
increased at 1 day (p ≤ 0.0156) and 30 days post-ischemia
(p ≤ 0.0077). The data were compared with the internal control values
for each time point in the disease progression. Magnification, 60; scale
bar, 20 μm; n = 3. The data were expressed as the mean ± SEM;
∗p < 0.05; ∗∗p < 0.004; ∗∗∗p < 0.001.
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FIGURE 7 | Proteins related to CMA and homeostasis are differentially
affected in AD and CI. Representative bands from SS-Cx lysates of 3xTgAD
and ischemic rats were evaluated by Western blotting (A) CHIP was unmodified,
(B) Hsc70 decreased at 12 months (p ≤ 0.302) and at 18 months (p ≤ 0.034),
(C) Hsp90 increased at 6 months (p ≤ 0.0409), (D) LAMP-2 levels were
unaltered in the 3xTg-AD mice. (E) CHIP was unmodified, (F) Hsc70 and
(H) LAMP2 increased at the intermediate stage (15 days) post-stroke (p ≤ 0.05).
(G) Hsp90 levels increased at 1 (p ≤ 0.0432) and 15 days (p ≤ 0.0093) and
decreased at 30 days (p ≤ 0.0076) after ischemia. The data were normalized
against the internal control for each time point in the NoTg mice and sham rats,
respectively. β-III tubulin and actin were used as the loading controls. The data
are shown in the bar graph as AUs. The data were compared to the internal
control values for each time point in the disease progression. The data are
presented as the mean ± SEM; n = 3–5; ∗p < 0.05; ∗∗p < 0.001.
AD and CI are neurological disorders characterized by protein
aggregation and neuronal death, which results in cognitive and
behavioral disorders (Wen et al., 2004; Golde and Miller, 2009;
Shelkovnikova et al., 2012). Tauopathy increases progressively
with age in AD animal models (Oddo et al., 2003) and in
the brains of AD patients (Diniz et al., 2008). The sustained
upregulation of various kinases, such as CDK5 kinase, JNK,
MAPK, and GSK3 (Planel et al., 2004), results in the formation of
PHFs and NFTs (Alonso et al., 1996) and leads to a disruption in
axonal transport (Grundke-Iqbal et al., 1986; Schindowski et al.,
2006; Iqbal and Grundke-Iqbal, 2008).
Akt and mTOR are essential homeostatic components that are
altered during chronic (AD) or acute (CI) neurological disease
(Meske et al., 2008; Chong et al., 2012). Akt is a pro-survival
protein that is triggered by cell stress during aging (Chong
et al., 2005) and by downstream eﬀectors that upregulate Bcl-2
(Levine et al., 2008), which was conﬁrmed in our study in the
oldest NoTg mice. In addition, activated Akt was detected at
the earliest stage (6 months) of the chronic lesion in the 3xTg-
AD model, which may be because of compensation (Datta et al.,
1999). However, recent evidence has conﬁrmed that β-amyloid
aggregates can generate the sustained activation of Akt, which
aﬀects the insulin response, tau phosphorylation (O’Neill et al.,
2012), and the downstream eﬀectors of the mTOR pathway that
control cell growth, proliferation, and survival (Chong et al.,
2010). Also, our data showed increasedmTOR activity in the early
and late stages of the 3xTg-AD model, suggesting that mTOR
activity in the late phase may be closely related to high levels of
hyperphosphorylated tau (Moreau et al., 2010; Caccamo et al.,
2013) and that decreased levels of Bcl-2 may be related to cell
death in the advanced stages of the disease (Rodriguez et al.,
2011).
Conversely, we observed decreased levels of p-Akt Ser473,
p-mTOR Ser2448, and mTOR activity concomitant with the
decline of tauopathy and neuronal loss at 30 days post-ischemia
in the absence of changes in Bcl-2 protein levels, suggesting
apoptotic regulation (Iadecola and Anrather, 2011). Previous
studies have reported that mTOR overactivation increases the
cerebral infarct size (Zhang et al., 2012), and a decrease in mTOR
activity reduces inﬂammation and nerve tissue damage and
facilitates motor recovery after an ischemic event (Sekiguchi et al.,
2012). In addition, Akt/mTOR inactivation promotes autophagy
(Chong et al., 2012), and the inhibition of mTOR results in
the degradation of hyperphosphorylated tau and NFTs through
autophagy (Majumder et al., 2011; Jiang et al., 2014).
Autophagy failure has been widely associated with
neurodegenerative diseases, which are characterized by the
accumulation of proteins in an age- or injury-dependent manner
(Madeo et al., 2009; Cuervo et al., 2010). Our ﬁndings suggest
alterations on autophagy markers in the late stage of 3xTg-AD,
resulting in increased levels of the Vps34 and Beclin-1 proteins
at 6 months. While, the loss of this association was observed
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in the 3xTg-AD mice at 18 months. Furthermore, recent
reports have demonstrated that these proteins are essential
for macroautophagy initiation via autophagosome formation
(Cebollero et al., 2012), and a loss of the association between
these proteins signiﬁcantly reduces macroautophagy (Kang et al.,
2011; Jaber and Dou, 2012). In addition, the levels of LC3B-II,
an autophagosome marker (Kabeya et al., 2000, 2004; Kuma
et al., 2007), was increased in the early stage (6 months) in the
3xTgAD mice. However, a signiﬁcant reduction was observed in
the oldest mice (18 months), indicating an inverse relationship
with tauopathy detected levels, which is supported by an inverse
correlation between autophagy-related markers downregulation
and the increase in tau aggregates (Meske et al., 2008; Majumder
et al., 2011; Schaeﬀer et al., 2012; Ozcelik et al., 2013).
The upregulation of Beclin-1 levels after an ischemic event
has been associated with the prevention of cell death by necrosis
and a reduction in infarct volume (Carloni et al., 2008), being
suggested Beclin-1 as a homeostatic regulator of autophagy post-
ischemia (Carloni et al., 2010; Ryter et al., 2013). However, the
speciﬁc role of Vps34 after acute injury remains unclear. Vps34
has been shown to contribute to exocytosis, autophagy, and
the activation of mTOR (Backer, 2008). How Vps34 interacts
with Beclin-1 to induce autophagosome formation is not clear
yet. However, a recent report suggest that the location of
Vps34 in speciﬁc cytoplasmic areas leads to autophagic vesicle
formation (Burman and Ktistakis, 2010). This hypothesis is
consistent with our observations of reduced levels of Vps34 total
protein that were strongly associated with Beclin-1 at 30 days
post-ischemia, which coincided with the decline of tauopathy
levels in this time point. These data are consistent with the
signiﬁcant increase in LC3B puncta detection and its inverse
relationship with hyperphosphorylated tau levels in the late phase
post-ischemia. Nonetheless, an increase in LC3B-II on the ﬁrst
day post-ischemia has been reported in neuronal degeneration
(Adhami et al., 2006; Li and McCullough, 2010), and it has
been suggested that the pharmacological inhibition of autophagy
reduces cerebral infarct volume (Kubota et al., 2010; Meloni
et al., 2011; Gao et al., 2012). However, autophagic activity may
play an important role in neuroprotection after an ischemic
event, resulting in a beneﬁcial eﬀect on the cerebral cortex and
hippocampus to prevent protein aggregation after stroke (Rami,
2009; Guo et al., 2010; Liu et al., 2010, 2013a,b; Zhou et al., 2011),
and autophagic degradation has been proposed as an important
regulator of hyperphosphorylated tau levels after an acute injury
(e.g., in CI; Liu et al., 2010; Marino et al., 2011; Schaeﬀer and
Goedert, 2012), which is consistent with our ﬁndings.
Moreover, CMA is activated under conditions of stress and is
an interdependent process that cross-talks with macroautophagy
via the upregulation of lysosomal proteins, such as Hsc70
and LAMP-2 (Gonzalez-Polo et al., 2005; Massey et al., 2006;
Kaushik et al., 2008). Hsp90 is strongly involved in the
hyperphosphorylation of tau in AD (Tortosa et al., 2009; Miyata
et al., 2011; Salminen et al., 2011; Jinwal et al., 2013) and
was increased in the 3xTg-AD mice at 6 months. However,
a signiﬁcant reduction in Hsc70 was observed in the older
3xTgAD mice (12 and 18 months). Hsc70 reduction has also
been associated with the blockage of CMA (Cuervo et al.,
1997; Kaushik et al., 2008) because Hsc70 is a substrate for
degradation in the lysosome (Li et al., 2011; Kaushik and Cuervo,
2012). Therefore, our results showed that a number of proteins
related to CMA, homeostasis, and cell survival were aﬀected
in the 3xTg-AD mice, which could enabling the aggregation of
hyperphosphorylated tau.
Previous studies have demonstrated an increase in the
expression of Hsc70, LAMP-2, and Hsp90 mRNAs, the proteins
function together to remove protein aggregates and block
neuronal apoptosis (Kobayashi et al., 2000) at 48 h after CI or
cerebral hypoxia (Kitagawa et al., 1990; Kirino et al., 1991; Tanaka
et al., 2002). These ﬁndings are consistent with our observations
of increased Hsc70, Hsp90, and LAMP-2 levels and unchanged
LC3BII levels in the intermediate stage post-ischemia (15 days).
In contrast, in the late stage (30 days), there was an increase of
macroautophagy-related marker, LC3BII, while there were not
signiﬁcant changes in the levels of Hsc70 and LAMP2 and a
signiﬁcant reduction in Hsp90 levels (Gonzalez-Polo et al., 2005;
Massey et al., 2006; Kaushik et al., 2008).
Taken together, our ﬁndings maybe could support that
the autophagic related markers indicate that this degradation
pathway could be involved in reverses tauopathy, promotes
cellular homeostasis, and plays a neuroprotective role via
the inhibition of the mTOR pathway in late-stage of 2-VO
CI model. These ﬁndings are in contrast to the decline of
autophagic-related markers observed in 3xTg-AD mice model,
which could enables tauopathy and neuronal loss at the late
stage, suggesting together a diﬀerential temporal approach
to the induction of neuroprotection and the prevention of
neurodegeneration. However, additional experiments are needed
for the understanding of the molecular mechanisms that regulate
the degradation of protein aggregates by autophagy pathway
according to the injury that alters cellular homeostasis.
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